Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Summary not available.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced senior management is traveling to South East Asia following a record monthly production of 1.3 metric tons of recombinant spider silk cocoons on April 13, 2026. The trip will review production quality, oversee downstream reeled-silk processing, and coordinate expansion with Prodigy Silk and the production network.
The company reiterated its near-term roadmap to scale toward a 10 metric ton monthly production target and highlighted leadership coverage in National Geographic.
Kraig Biocraft Laboratories (OTCQB: KBLB) reported deploying 700,000 BAM-1 Alpha production hybrids and producing >1.3 metric tons of recombinant spider silk cocoons in a single month (April 2026), a fivefold record increase. Management targets a near-term goal of 10 metric tons per month, moving from research to industrial-scale production.
The milestone validates the company’s vertically integrated platform—from genetic design to cocoon production—and signals potential commercial applications across textiles, aerospace, medical devices, and sustainable materials, while noting scaling, infrastructure, and demand-development challenges.
Kraig Biocraft Laboratories (OTCQB: KBLB) produced over 1.3 metric tons of recombinant spider silk cocoons in a single month on April 6, 2026, a fivefold increase over its prior record. The company says this validates its scale-up strategy and advances its plan to reach 10 metric tons per month within coming months.
Expanded facilities, new BAM-1 Alpha production hybrids, and vertically integrated operations reportedly enabled the ramp without operational disruptions.
Kraig Biocraft Laboratories (OTCQB: KBLB) is scaling its transgenic silkworm platform toward apparel-first commercialization by deploying ~1,000,000 proprietary spider-silk silkworm eggs and ramping three Vietnam facilities.
The company targets up to 10 metric tons of recombinant spider-silk cocoons per month and reports fibers with tensile strength up to 1.79 GPa.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the deployment of more than 700,000 BAM-1 Alpha production hybrids from a previously reported 1,000,000 egg inventory on March 30, 2026. The silkworms are now in active production as part of an aggressive, milestone-driven scale-up plan aimed at reaching metric ton output levels.
Management says the BAM-1 Alpha hybrids are exceeding internal expectations for robustness and productivity, and the Company reports this release as a key execution milestone toward industrial-scale recombinant spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) expanded its R&D capacity for Project Atlas on March 23, 2026, roughly tripling screening throughput and adding staff and advanced equipment.
The upgrades automate testing workflows, strengthen analytical assays, increase parallel transgenic line evaluation, and aim to shorten development timelines and accelerate selection of production candidates.
Kraig Biocraft Laboratories (OTCQB: KBLB) says it deployed one million genetically engineered silkworm eggs across Vietnam to scale production of recombinant spider-silk cocoons, with a stated potential output near 10 metric tons per month. The company reported pilot shipments to several unannounced global brands and laboratory samples with tensile strengths near 1.8 GPa and elasticity above 38%.
The program combines traditional sericulture with transgenic silkworms and explores replacing native silk genes with spider sequences for purer spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced that Project Atlas, its next-generation bioengineering program, has passed a critical milestone and is advancing to the next phase. The program produced multiple new transgenic lines and aims to create novel spider-silk-based materials for industrial and defense uses.
The company noted Project Atlas merges multiple genetic elements into an integrated architecture to deliver enhanced strength, toughness, and other performance properties.
Kraig Biocraft Laboratories (OTCQB:KBLB) gained national visibility after its recombinant spider silk platform was featured on National Geographic’s March 2026 cover. Kraig plans to deploy ~1 million proprietary silkworm eggs across three Vietnam facilities targeting up to 10 metric tons of cocoons per month from March.
Other market moves include Gilead’s definitive acquisition offer for Arcellx and ImmunityBio reporting strong ANKTIVA revenue growth.